Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

e (CHF) and new onset CHF have been reported with TNF blockers.  Certolizumab pegol has not been formally studied in patients with CHF.  Exercise caution when using certolizumab pegol in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following certolizumab pegol administration.  If such reactions occur, discontinue further administration of certolizumab pegol and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including certolizumab pegol, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal.  Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating certolizumab pegol therapy.  Exercise caution in prescribing certolizumab pegol for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment.  In patients who develop HBV reactivation, discontinue certolizumab pegol and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic Reac
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast, 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:7/29/2014)... 2014 Numotion,s Board of Directors has announced that ... be the company,s new Chief Executive Officer. ... GE where he worked primarily for GE Healthcare Services, running ... $5 billion. His most recent position was as President and ... am thrilled to join Numotion," said Mike Swinford . ...
(Date:7/29/2014)... 29, 2014 McGraw-Hill Education Professional, a leading ... technical, and medical communities, has announced the launch of ... application of the world-renowned medical education platform. ... App , available for download onto all iOS and ... to gain access to valuable AccessMedicine diagnostic ...
Breaking Medicine Technology:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3
... GARDEN CITY, New York, Oct. 7 ... Merkin recognize and congratulate seniors enrolled with HCP, IPA ... concern, health care reform, directly to members of Congress, ... http://www.newscom.com/cgi-bin/prnh/20091007/LA89266 ) , Dr. John Gastright, Senior ...
... , WALTHAM, Mass., Oct. 7 Nova Biomedical Corporation, ... that the company,s independent, wholly owned subsidiary, Sanvita CBGM, ... Sanvita, Inc., a subsidiary of CCS Medical, Inc. ... through this transaction, Nova,s Consumer Blood Glucose Monitoring (CBGM) ...
Cached Medicine Technology:HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 2HealthCare Partners, IPA, Dr. Richard Merkin, CEO, Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington, DC 3Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medical's Subsidiary, Sanvita, Inc. 2
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July ... on a task, various brain connections fire up. But ... with autism, according to a small new study. ... even less of this "brain flexibility," the researchers found. ... when children with autism are faced with new situations," ...
(Date:7/29/2014)... The Board of Governors of the State Bar ... Connie Akridge to serve as a trustee of ... the Foundation. Akridge served as President of the State Bar ... Holland & Hart in Las Vegas, providing tailored counsel on ... and healthcare clients for more than 25 years. She regularly ...
(Date:7/29/2014)... 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. , The study finds that the ...
(Date:7/29/2014)... The Law Offices of Michael Cordova is proud to ... organization providing grief camps for kids, teens, adults, and families. ... clients experience from the death of a loved one. ... Stepping Stones of Hope, as they provide hope and healing ... also includes a monthly support group and a variety of ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Holland & Hart LLP Attorney Connie Akridge Reappointed Trustee of the Nevada Bar Foundation 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:The Law Offices of Michael Cordova is Sponsoring Stepping Stones of Hope, a Non-Profit Organization Providing Grief Camps for Kids, Teens, Adults, and Families 2
... April 27 BioTrends is pleased to announce the ... SIMPONI (R) . Cenotcor ... for SIMPONI (R) (generic name: golimumab) ... anti-TNF-alpha therapy, SIMPONI is approved for the treatment of ...
... WASHINGTON, April 27 Speaker Nancy ... virus: "This afternoon, Majority Leader Hoyer and I were ... Obama Administration,s preparations to deal with the public health ... briefed us on the efforts that are being made ...
... 27 Speaker Nancy Pelosi released the following statement ... serve as Ambassador at Large and Global AIDS Coordinator:"President ... Ambassador at Large and Global AIDS Coordinator signals the ... Dr. Goosby is an excellent choice and is uniquely ...
... April 27 Young Innovations, Inc. (Nasdaq: YDNT ... 2009. Sales for the first quarter of 2009 were ... the $24.4 million reported in the first quarter of 2008. ... first quarter of 2009 from $4.6 million in the first ...
... BAX ), will host its annual shareholders meeting ... (10:30 a.m. Central Time)This call is being webcast by Thomson/CCBN ... http://www.baxter.com/ . The conference call ... It cannot be recorded or rebroadcast without Baxter,s permission.The webcast ...
... HSKA ) announces the following Webcast: (Logo: ... to Its Annual Meeting of Stockholders on the WebWhen: ... www.heska.com (click on the Annual Meeting of ... Live over the Internet -- Simply log on ...
Cached Medicine News:Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 2Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 3Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 4Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 5Health News:Young Innovations, Inc. Announces Results for the Quarter Ended March 31, 2009 6Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: